Bio World 2011 - China's largest conference and exhibition dedicated to the burgeoning biopharmaceutical industry will bring together CEOs and senior executives from China and the rest of the world’s top 300 biopharmaceutical companies. They will discuss and debate on business strategies, explore biotherapeutics R&D partnership opportunities, as well as exchange insights in biomanufacturing and cell culture engineering best practices.

This 2nd annual event will be held in Shanghai Raddison Pudong Hotel from 29th Nov to 1st Dec 2011, hosted by IMAPAC.

Lately, big pharmas have been rapidly increasing their biologic business presence in the China market through direct investments and strategic partnerships. Merck, for example, started construction of a 1.1 billion RMB ($162 million) manufacturing site in Hangzhou, followed by the signing of a mutual corporation agreement with local vaccine giant Sinopharmin July 2010. Richard T. Clark, chairman and chief executive officer, Merck, said “Expanding our business in emerging markets throughout the world is critical to the mission and growth of Merck/MSD and innovative partnerships are a key element of our approach.”

They are not alone.GSK, Sanofi Pasteur, Novartis and Novo Nordiskhave also declared their ambitionsto win the Chinese biopharmaceutical market.

Interestingly,at the same time, several Chinese home grown pharmaceuticalgiants are also taking big steps inthe same direction. On July 31st2010, Shandong Province-based LuyePharma Group Co. Ltd. announced plans to acquire an 80 percent stake in Singapore's A-Bio PharmaPte Ltd. for $7.36 million, marking Luye’s entrance into the biologics business, headed by CEO of A-Bio, Steven Lee.

Supported by leading regional development agencies and bioparks such as BioBay, BIOasis and BioLake in China and biopharma industry associations such as the Sino-American Pharmaceutical Professionals Association(SAPA) and Chinese-American BioMedical Assocation (CABA), Bio World China will bring togetherbiopharma industry leaders from diversejob functions through 4 co-located conferences: BioManufacturing World, BioTherapeutic World, Cell Culture Engineering World and BioPharma CEO conclave.

For the first time in China, CEOs from top 60 Chinese home grown biopharmas will gather in a closed-door intimate discussion to shape the future of the industry.Confirmed CEO participants includeWang Weiquan of Harbin Pharmaceutical Group, Henry Lee of Guangdong Techpool Bio-Pharma, Su Chen of Chengdu Kanghong Pharmaceutical Group, Chai Xiangdong of Shenzhen Neptunus Interlong Bio-Tech, just to name a few.

Aimedat the cause to facilitate innovation and manufacturing of affordable and high quality vaccine and biologic drugs in China, Bio World Chinaserves to be the definitive meeting platform for China’s biopharma industry leaders.

Some of key issues to be discussed include:

1. Biosimilars and biobetters development strategies and advancements;

2. Novel biotherapeutic development in China and partnership opportunities;

3. Regulatory updates and GMP compliance case studies;

4. Novel approaches to cell line engineering and selection;

5. Best practices in culture media formulation and optimization;

6. Downstream processing economy and new advancements;

7.New and next generation immunotherapeutics and therapeutic vaccines development;

8. Achieving operational excellence through innovativeQuality by Design (QbD), Process analytical technologies(PAT) and Design of Experiments (DoE) practices;

9. Single-use/disposable technologies and implementation in bioprocessing;

10. Cold chain strategies and best practices for biologics.